News – AKL Therapeutics

APPA shows promise in age related diseases

New data presented at the 2023 Osteoarthritis Research Society International (OARSI) World Congress in Denver, Colorado (March 17th-20th) suggests that AKL Therapeutics’ investigational oral osteoarthritis (OA) drug APPA may have a dual effect on senescence – a process in which cells stop dividing as a natural consequence of ageing. Senescence plays a major role in the development of many […]

Interview with Longevity Technology

Osteoarthritis affects one in seven adults in the US, with more than half of patients of working age. There are currently no effective and well tolerated oral therapies that provide long term relief for the symptoms of OA or reduce its progression. With APPA, AKL believes it has the only drug with a mechanism of action […]

OARSI 2023 Presentation

AKL’s data on the effect of APPA in reducing cellular senescence in articular chondrocytes conducted by INIBIC (Instituto de Investigación Biomédica de A Coruña) has been published at OARSI 2023, the leading global osteoarthritis conference being held in Denver, Colorado. Copy of the poster is avaliable – please click here. OARSI is a key congress […]

New Senomorphic Patent Filed

Senescence is a process in which ageing cells stop dividing and is involved in many diseases of ageing. Over time senescent cells build up in tissues and release harmful substances causing inflammation and damage to healthy cells. The development of OA correlates with a rise in the number of senescent cells in joint tissues. Laboratory […]

Phase 2a Human Trial Key Findings

AKL has completed analysis of a Phase 2a, 28-day 150 patient, trial of oral APPA in osteoarthritis (OA) of the knee. The data from this Phase 2a trial adds considerably to our understanding of APPA. The trial was designed to assess the efficacy of APPA in subjects with varying degrees of osteoarthritis and, in predefined […]

EULAR & OARSI 2022 Presentations

AKL’s data on APPA’s Phase IIa Human Clinical Trial, ‘The Efficacy & Safety of APPA in Symptomatic Knee Osteoarthritis’, was presented as a scientific abstract and as a poster at the congress for European Alliance of Associations for Rheumatology (EULAR) 2022. The APPA phase IIa trial was designed to assess the efficacy of APPA in […]